Nutriband Inc. Common Stock
NTRBNutriband Inc. (NTRB) is a specialty pharmaceutical company focused on developing and commercializing transdermal drug delivery technologies. The company aims to provide innovative solutions for controlled-release medication delivery, improving patient compliance and treatment outcomes. Nutriband leverages proprietary patches and delivery systems to address various medical needs across multiple therapeutic areas.
Company News
Nutriband Inc. reported significant progress in 2025 including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M with no shareholder dilution, a 25% preferred stock dividend, and major advances in its lead product AVERSA Fentanyl abuse-deterrent patch. The company received FDA Type C Meeting approval, completed manufacturing sca...
Nutriband Inc. announced the sale of a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million USD, with Nutriband shareholders retaining 10% ownership. The company plans to use proceeds to develop AVERSA Fentanyl, an abuse-deterrent opioid patch with potential annual US sales of $80-200 million. EarthVision Bio is dev...
Nutriband met with the FDA to discuss its AVERSAâ„¢ FENTANYL abuse deterrent patch, receiving guidance on regulatory pathway, manufacturing, and clinical study plans for a potential first-of-its-kind worldwide abuse deterrent fentanyl patch.
Nutriband has partnered with Brand Institute to develop a commercial brand name for its lead product, an abuse deterrent fentanyl transdermal patch utilizing AVERSAâ„¢ technology, aimed at preventing drug misuse and accidental exposure.
EmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.
